Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice

References

• Megna M, Cinelli E, Camela E, et al. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599–620.
   PubMed Web of Science ®Google Scholar
• Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2020;1–10. doi: 10.1080/09546634.2020.1729335.
   Web of Science ®Google Scholar
• Carrascosa JM, Theng C, Thaçi D. Spotlight on topical long-term management of plaque psoriasis. Clin Cosmet Investig Dermatol. 2020;13:495–498.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psoriasis: assessment and management; 2012 [cited 2019 Nov 1]. Available from: https://www.nice.org.uk/Guidance/CG153.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659.
   PubMed Web of Science ®Google Scholar
• Thaçi D, de la Cueva P, Pink AE, et al. Calzavara-Pinton P. General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. BJGP Open. 2020;4(5):bjgpopen20X101108.
   PubMedGoogle Scholar
• Svendsen MT, Jeyabalan J, Andersen KE, et al. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017;28(5):374–383.
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Calzavara Pinton P, Cristaudo A, et al. Back to the future: a new topical approach for mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018;153(3):375–382.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Manfredini S, Borghi A, et al. How to improve adherence to treatment in patients with mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018;153(5):692–697.
   PubMed Web of Science ®Google Scholar
• Kuehl B, Shear NH. The evolution of topical formulations in psoriasis. Skin Therapy Lett. 2018;23(4):5–9.
   PubMedGoogle Scholar
• Bonnekoh B, Fernández García JJ, Surber C, et al. Innovation that drives your dermatological future. EMJ Dermatol. 2017;5(1):36–43.
   Google Scholar
• Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis-an emerging concept. Allergy. 2009;64(2):276–278.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269–1277.
   Web of Science ®Google Scholar
• Smith D. Fumaric acid esters for psoriasis: a systematic review. Ir J Med Sci. 2017;186(1):161–177.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805–811.
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2012; 26(Suppl 3):1–10.
   PubMedGoogle Scholar
• Augustin M, Mrowietz U, Bonnekoh B, et al. Topical longterm therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12(8):667–682.
   Web of Science ®Google Scholar
• Benezeder T, Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol. 2019;41(6):633–644.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Fuentes-Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131(2):391–400.
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48–54.
   PubMed Web of Science ®Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465–471.
   PubMed Web of Science ®Google Scholar
• Segaert S, Ropke M. The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis. J Drugs Dermatol. 2013;12(8):e129-37–e137.
   PubMedGoogle Scholar
• Segaert S, Shear NH, Chiricozzi A, et al. Optimizing anti-Inflammatory and immunomodulatory effects of corticosteroid and vitamin D analogue fixed-dose combination therapy. Dermatol Ther. 2017;7(3):265–279.
   Web of Science ®Google Scholar
• Fujiyama T, Ito T, Umayahara T, et al. Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion. J Allergy Clin Immunol. 2016;138(2):517–528.e5.
   PubMed Web of Science ®Google Scholar
• Lovato P, Norsgaard H, Tokura Y, et al. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153–164.
   PubMed Web of Science ®Google Scholar
• Lovato P, Jiang L, Hebsgaard J, et al. Calcipotriol/betamethasone dipropionate foam inhibits Th17 cytokine secretion and improves epidermal barrier markers in a human Th17 skin inflammation model. Dermatol Ther. 2021;11(1):265–274.
   Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729.
   PubMed Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther. 2016;6(3):413–425.
   PubMed Web of Science ®Google Scholar
• Kim ES, Frampton JE. Calcipotriol/betamethasone dipropionate foam: a review in plaque psoriasis. Drugs. 2016;76(15):1485–1492.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Olesen M, Villumsen J, et al. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35(4):239–245.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. L. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) Plus betamethasone dipropionate 0.064% (BD) is more efficacious than cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41.
   PubMedGoogle Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris-a randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. L. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health-related quality of life in patients with psoriasis vulgaris: results from the randomized PSO-FAST study. J Drugs Dermatol. 2016;15(8):981–987.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Bang B, Clonier F, et al. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments. J Eur Acad Dermatol Venereol. 2016;30(11):1951–1956.
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Lebwohl M, Menter A, et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15(8):951–957.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Koo J, et al. Fixed-Combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15(2):119–124.
   PubMedGoogle Scholar
• Seyger M, Abramovits W, Liljedahl M, et al. Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial. J Eur Acad Dermatol Venereol. 2020;34(9):2026–2034.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Krakor M, Anger T, et al. Prospective, observational, Non-Interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233(6):425–434.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Veverka KA, Lu M, et al. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. J Dermatolog Treat. 2019;30(5):454–460.
   PubMed Web of Science ®Google Scholar
• Pinter A, Thormann H, Angeletti F, et al. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;11:451–459.
   PubMed Web of Science ®Google Scholar
• Gallo L, Megna M, Cirillo T, et al. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. J Eur Acad Dermatol Venereol. 2019;33(7):1312–1315.
   PubMed Web of Science ®Google Scholar
• Anderko M, Navarro Triviño FJ, Sharples CL. Calcipotriol plus betamethasone dipropionate aerosol foam for scalp psoriasis. Clin Cosmet Investig Dermatol. 2019;12:699–705.
   PubMed Web of Science ®Google Scholar
• Giovene GL, Giacomelli L, AIDA (Italian Association of Outpatient Dermatologists) Working Group. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice? G Ital Dermatol Venereol. 2018;153(6):872–876.
   PubMed Web of Science ®Google Scholar
• Amat-Samaranch V, Puig L. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):423–432.
   PubMed Web of Science ®Google Scholar
• Dattola A, Silvestri M, Bennardo L, et al. A novel vehicle for the treatment of psoriasis. Dermatol Ther. 2020;33(1):e13185.
   PubMed Web of Science ®Google Scholar
• Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Stein Gold L, Cambazard F, et al. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol. 2018;28(3):356–363.
   PubMed Web of Science ®Google Scholar
• Foley P, Garrett S, Ryttig L. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis. Curr Med Res Opin. 2018;34(7):1277–1283.
   PubMed Web of Science ®Google Scholar
• Balak DMW, Carrascosa JM, Gregoriou S, Calzavara-Pinton P, et al. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven european countries. J Dermatolog Treat. 2020;6:1–8.
   Google Scholar
• Calzavara-Pinton P, Kircik L, Jalili A, et al. Patients with psoriasis receiving long-term proactive or reactive management with fixed-dose combination CAL/BD foam showed sustained improvement in DLQI, PSI and EQ-5D scores, with significantly greater improvement in the proactive group. Presented at EADV; 2020. p. 29–31, Virtual.
   Google Scholar
• Thaçi D, Tyring S, de la Cueva P, et al. Patient-reported outcomes in remission versus relapse in patients with psoriasis receiving treatment with fixed-dose combination CAL/BD foam from the PSO-LONG trial. Presented at EADV, Virtual; 2020 October. p. 29–31.
   Google Scholar
• Papp K, Guenther L. Liljedahl M. Proactive treatment of plaque psoriasis with twice-weekly topical CAL/BD foam is safe in patients undergoing HPA-AXIS testing. Presented at EADV 2020, virtual. 2020 October. p. 29–31.
   Google Scholar
• Stein-Gold L, Alonso-Llamazares J, Laws P, et al. Proactive management with twice-weekly topical cal/BD foam prolongs treatment efficacy versus reactive management in patients with plaque psoriasis. Presented at EADV, Virtual. 2020 October. p. 29–31.
   Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (dovobet/daivobet/taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Camplone G, D'Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30–33.
   PubMed Web of Science ®Google Scholar
• Iversen L, Kurvits M, Snel-Prentø AM, et al. Calcipotriol/betamethasone dipropionate cutaneous foam treatment for psoriasis in patients with BSA 5–15% and PGA ≥ 3: post-hoc analysis from three randomized controlled trials. Dermatol Ther. 2020;10(5):1111–1120.
   Web of Science ®Google Scholar
• Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019;33(6):1116–1123.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Kircik LH. The effect of calcipotriene-betamethasone dipropionate aerosol foam versus vehicle on target lesions in moderate severity plaque psoriasis: focus on elbows and knees. J Drugs Dermatol. 2019;18(4):358–361.
   PubMed Web of Science ®Google Scholar
• Petersen B, Lebwohl M. Treating scalp psoriasis with calcipotriene/betamethasone dipropionate fixed-dose combination cutaneous foam: review of phase 2 data. J Drugs Dermatol. 2020;19(8):784–786.
   PubMed Web of Science ®Google Scholar
• Patel DS, Veverka KA, Hansen JB, et al. Efficacy of fixed-combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam for scalp plaque psoriasis: additional analysis of a phase II, randomized clinical study. J Clin Aesthet Dermatol. 2020;13(5):18.
   Google Scholar
• Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018;17(8):845–850.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Schlesinger TE, Tanghetti E. Efficacy and safety of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam with apremilast for moderate plaque psoriasis. J Drugs Dermatol. 2020;19(9):874–880.
   PubMed Web of Science ®Google Scholar
• Haidari W, Pona A, Feldman SR. Management of residual psoriasis in patients on biologic treatment. J Drugs Dermatol. 2020;19(2):188–194.
   PubMed Web of Science ®Google Scholar
• Rovati C, Arisi M, Venturini M, et al. Combination with an aerosol foam containing calcipotriene and betamethasone is a simple way to strongly improve treatment results of narrow-band UVB phototherapy. Eur J Dermatol. 2021; in press.
   PubMedGoogle Scholar
• WHO. 2003. Adherence to long-term therapies: evidence for action [cited 2021 Feb 14]. Available from: https://www.who.int/chp/knowledge/publications/adherence_report/en/.
   Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, PSO-TOP study group, et al. A topical treatment optimization programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197–205.
   PubMed Web of Science ®Google Scholar
• Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9(1):5–18.
   PubMed Web of Science ®Google Scholar
• Eicher L, Knop M, Aszodi N, et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253–2263.
   PubMed Web of Science ®Google Scholar
• Caldarola G, De Simone C, Moretta G, et al. Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients. J Dermatolog Treat. 2017;28(8):722–725.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Andersen KH, et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol. 2018;179(5):1062–1071.
   PubMed Web of Science ®Google Scholar
• Armitage LC, Kassavou A, Sutton S. Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis. BMJ Open. 2020;10(1):e032045.
   PubMed Web of Science ®Google Scholar
• Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017;31(11):1876–1883.
   PubMed Web of Science ®Google Scholar
• Vender R, Gooderham MJ, Guenther LC, et al. Psoriasis patients' preference for an aerosol foam topical formulation. J Eur Acad Dermatol Venereol. 2018;32(11):e400–e401.
   PubMed Web of Science ®Google Scholar
• Velasco M, González-Fernández D, Rodriguez-Martín M, et al. Patient and physician satisfaction with calcipotriol and betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis on the Body. Actas Dermosifiliogr. 2019;110(9):752–758.
   PubMed Web of Science ®Google Scholar